EU seals €63m Deal with Gilead Sciences to Secure Remdesivir’s Supply for the Region

The European Commission sealed a 63 million-euro ($74 million) deal with the US-based Gilead Sciences procure supplies of the company’s antiviral drug Remdesivir for the region. Remdesivir has prove to be successful in treating the infection caused by coronavirus. As per the agreement signed on Tuesday, the EU nations and UK would start receiving the doses of Veklury, the brand name for Remdesivir, from August onwards.

The EU is aiming to provide the anti-viral dose to about 30,000 patients who have been diagnosed with “severe” Covid-19 symptoms.

The EU Commissioner for health and safety Stella Kyriakides said, “The Commission has been working tirelessly with Gilead to reach an agreement to ensure that stocks of the first treatment authorised against COVID-19 are delivered to the EU. A contract has been signed yesterday, less than a month after the authorisation of Remdesivir, which will allow the delivery of treatments from early August for thousands of patients.”

She added, “The Commission is leaving no stone unturned in its efforts to secure access to safe and efficient treatments, and is supporting the development of vaccines against coronavirus. Yesterday’s agreement is another important step forward in our fight to overcome this disease”.

“The Commission is now preparing a joint procurement for further supplies of the medicine, expected to cover additional needs and supplies as from October onwards,”the statement said.

On 3 July, Remdesivir successfully gained the authorisation for conditional marketing for the first to be used for the treatment of Covid-19 infection. This authorisation would enable getting early access to medicines in case of public health emergency, such as the current pandemic. European Medicines Agency (EMA) recommenced the use of medicine against COVID-19 for adults and adolescents as from age 12 suffering from pneumonia who need supplemental oxygen. Remdesivir has also received approval from the US and Japanese government. As per of the agreement, despite the approval, the Union said that the drug would be monitored by the health department to ensure the patients’ safety. Also, in order to move to full authorisation from current conditional authorisation, Gilead has also been requested to submit the final reports of the Remdesivir studies to the EMA by December 2020.

Read more article here :

Leave a Reply

Your email address will not be published. Required fields are marked *